Caffeine consumption and risk of dyskinesia in CALM-PD

Mov Disord. 2013 Mar;28(3):380-3. doi: 10.1002/mds.25319. Epub 2013 Jan 21.

Abstract

Background: Adenosine A2A receptor antagonists reduce or prevent the development of dyskinesia in animal models of levodopa-induced dyskinesia.

Methods: We examined the association between self-reported intake of the A2A receptor antagonist caffeine and time to dyskinesia in the Comparison of the Agonist Pramipexole with Levodopa on Motor Complications of Parkinson's Disease (CALM-PD) and CALM Cohort extension studies, using a Cox proportional hazards model adjusting for age, baseline Parkinson's severity, site, and initial treatment with pramipexole or levodopa.

Results: For subjects who consumed >12 ounces of coffee/day, the adjusted hazard ratio for the development of dyskinesia was 0.61 (95% CI, 0.37-1.01) compared with subjects who consumed <4 ounces/day. For subjects who consumed between 4 and 12 ounces/day, the adjusted hazard ratio was 0.73 (95% CI, 0.46-1.15; test for trend, P = .05).

Conclusions: These results support the possibility that caffeine may reduce the likelihood of developing dyskinesia.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine A2 Receptor Antagonists / administration & dosage*
  • Adenosine A2 Receptor Antagonists / metabolism
  • Aged
  • Antiparkinson Agents / adverse effects*
  • Benzothiazoles / adverse effects*
  • Caffeine / administration & dosage*
  • Caffeine / metabolism
  • Cohort Studies
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Dyskinesia, Drug-Induced / etiology
  • Dyskinesia, Drug-Induced / prevention & control*
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Levodopa / adverse effects*
  • Male
  • Middle Aged
  • Parkinson Disease / drug therapy
  • Pramipexole
  • Proportional Hazards Models
  • Retrospective Studies
  • Risk

Substances

  • Adenosine A2 Receptor Antagonists
  • Antiparkinson Agents
  • Benzothiazoles
  • Caffeine
  • Levodopa
  • Pramipexole